Regorafenib (Stivarga) Shows Promise in Patients With Advanced HCC

In a recent interview with Reuters Health, Dr. Anton Bilchik weighed in on the drug Stivarga’s (regorafenib) ability to improve survival in patients with advanced hepatocellular carcinoma (HCC). As chief of medicine and of gastrointestinal research at John Wayne Cancer Institute at Providence Saint John’s Health Center in Santa Monica, California, Dr. Anton Bilchik told Reuters Health, “This landmark study . . . is the first . . . to demonstrate that a new anti-angiogenesis drug had a significant survival benefit in those patients who progressed on sorafenib.” To find out what else Dr. Anton Bilchik had to say, please read the full article:

https://www.mdalert.com/news/article/regorafenib-an-option-when-hcc-progresses-on-sorafenib